Sofinnova Partners Appoints Mats Eklund as Partner and Chief Operating Officer
10.11.2022 19:30:00 EET | Business Wire | Press release
Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced today the appointment of Mats Eklund as Partner and Chief Operating Officer, effective immediately. Mr. Eklund will be taking over the helm of Sofinnova’s corporate services team from Monique Saulnier, a Managing Partner. Ms. Saulnier, who is retiring after 40 years with Sofinnova, will remain at the firm for a transition period until the second half of 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221110005234/en/
Mats Eklund (Photo: Business Wire)
Mr. Eklund has 25 years’ experience in finance. His appointment reflects the strengthening of the firm’s management and corporate functions as it pursues its expansion across the entire value chain of life sciences investments.
Mr. Eklund most recently served as a Senior Advisor to two fund managers, NREP, a real estate fund manager with €15 billion in assets under management (AUM), and Sprints Capital, a venture capital and growth capital investment company with €1B in AUM. At NREP, he played a leading part in the acquisition of a German credit platform and in building the foundation for NREP’s credit business.
Before that, Mr. Eklund was Chief Operating Officer and Chief Financial Officer of Triton, a Northern European private equity and credit investment firm with €16 billion in AUM. He was responsible for the corporate services teams, risk management, portfolio monitoring and ESG and served as a Director of the Boards of the Triton Alternative Investment Fund Manager and General Partner Companies. In addition, he worked closely with the Investor Relations team, supporting fund formation, capital raising and key investor relationships. During his time as Triton’s COO, Mr. Eklund also served as Head of WestPark Management Services, a company dedicated to providing services to Triton’s portfolio companies.
Prior to joining Triton, Mr. Eklund was with GE for almost 14 years. His most recent role there was as Chief Financial Officer for GE Capital EMEA, M&A and Private Equity. Mr. Eklund holds a master’s in economics and financial administration from the School of Business, Economics and Law at Gothenburg University, Sweden.
Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said: “Mats’ arrival fits perfectly with our desire to further strengthen our corporate services organization. He brings a strong and varied set of skills to support the expansion of our European platform of strategies.”
Mr. Eklund commented: “I am delighted to join Sofinnova Partners at this pivotal time for life sciences investing. I’m looking forward to working with my new colleagues to develop our platform of funds, and I am grateful to Monique, who has a deep knowledge of the VC world and Sofinnova’s history, for staying on during the transition period.”
Ms. Saulnier said: “After four decades with Sofinnova, I am beginning my long goodbye with pride in my heart. The last few years of expansion have been a fascinating end to an exhilarating journey. I will retire in 2023 with the assurance that my legacy is in good hands with Mats.”
###
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221110005234/en/
Contact information
Bommy Lee
Head of Communications
Sofinnova Partners
blee@sofinnovapartners.com
+33 (0) 6 47 71 38 11
North America
RooneyPartners LLC
Kate Barrette
kbarrette@rooneypartners.com
+1 212 223 0561
France
StrategiesImage
Anne Rein
anne.rein@strategiesimage.com
+33 (0) 6 03 35 92 05
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy8.6.2026 09:00:00 EEST | Press release
Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it." Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engin
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 07:00:00 EEST | Press release
BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 14:00:00 EEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 13:41:00 EEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom